Researchers from Chulalongkorn University have successfully established a novel human antibody heavy chain variable (VH)-only domain with potent activity against folate receptor alpha-positive solid tumor in CAR-T cell format. Second-generation FRalpha-targeted VH-based and scFv-based CAR-Ts show specifically target and kill ovarian cancer cells in dose- and time-dependent manners. Meaningfully, VH-based CAR-T cells elicited superior antitumor potency and persistence in tumor rechallenge experiment and displayed fewer exhausted T cells after 4 rounds of stimulation, as compared with their scFv-based counterparts.
This current research highlights the benefits of utilizing VH domain antibody in CAR-T immunotherapy, particularly in targeting tumor antigens, and explores development strategies for treating solid tumors.
เงินทุน
This research was supported by the Second Century Fund (C2F), Chulalongkorn University.
กระดาษต้นฉบับ
ชื่อบทความต้นฉบับ: Efficiently targeting folate receptor alpha-positive ovarian cancer by human antibody VH domain-based chimeric antigen receptor (CAR)
วารสาร: JThe 29th Annual Meeting of Japanese Association of Cancer Immunology
ดอย: https://jaci2025.com/en/index.html